Titan Spine said today it won a new technology ICD-10 code from the U.S. Centers for Medicare & Medicaid Services, which allows for nanotextured surfaces on interbody fusion devices, clearing its nanoLOCK surface technology for coverage.
The code, approved as an XRG code, will go into effect and be usable on October 1 this year, and came based on information presented by Titan Spine on its nanoLOCK surface tech.
“We are very pleased with the new nanotextured category designation that CMS has created. And I am extremely proud of the entire Titan team who worked tirelessly to create our nanoLOCK surface technology and to procure its code,” CEO Dr. Peter Ullrich said in a press release.
Titan Spine said that, in the future, other technologies could be added to the code, but they would be required to demonstrate equivalence or superiority to the nanoLOCK system.
Last month, Titan Spine said it is expanding its spinal device warranty to include free replacement if its Endoskeleton interbody fusion devices delaminate or generate particulate debris during implantation.
The Mequon, Wisc.-based company said it amended its warranty, which it launched in 2014, based on its “confidence in its proprietary subtractive manufacturing process.
A study recently published in The Spine Journal indicated that the company’s Endoskeleton titanium interbody fusion devices generated no particulate debris or delamination during a simulated impaction to the disc space, Titan Spine said.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.